Clinical Trial Update: A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of low-dose ladostigil in mild cognitive impairment and dementia has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Dementia

Drugs mentioned

• Ladostigil (ladostigil)

Snippet

Sponsor: Avraham Pharmaceuticals Ltd | Conditions: Mild Cognitive Impairment, Dementia | Phase 2 | Status: COMPLETED | Results posted: 2017-06-15